An assessment of NO atmospheric air pollution over three cities in South Africa during 2020 COVID-19 pandemic.

Air Qual Atmos Health

Unit for Environmental Sciences and Management, North-West University, Private Bag X6001, Potchefstroom, South Africa.

Published: October 2022

To contain the spread of COVID-19 in 2020, several governments around the world imposed national lockdowns including that of South Africa. The purpose of this study was to investigate and give an overview of nitrogen dioxide column levels during the year 2020 over three South African cities (Johannesburg, Durban and Cape Town) using AURA OMI derived measurements, the HYSPLIT model, complemented with NCEP/NCAR reanalysis data. Our findings were that in 2020, all the cities recorded their daily maximum mean NO column levels during the winter season at 14.1 × 10 molecules per cm, 3.1 × 10 molecules per cm and 1.7 × 10 molecules per cm for Johannesburg, Durban, and Cape Town respectively. Across all seasons, Cape Town recorded the lowest seasonal mean at 0.6 × 10 molecules per cm (summer 2020) while the highest seasonal mean was recorded over Johannesburg at 9 × 10 molecules cm (winter 2020). Furthermore, an interannual comparison analysis indicated that during summer, there were increases of 6%, 1% and 30% for Johannesburg, Durban and Cape Town respectively. During winter, Johannesburg saw an increase of 19% while a 2% increase was recorded in Durban with Cape town recording a 16% decrease in NO column levels. The study also recorded that Cape Town and Durban were mainly influenced by long-range transport air masses originating from the South Atlantic Ocean, South America, Antarctica and the Indian Ocean particularly during the summer and autumn seasons possibly leading to the formation of marine nitrate aerosols.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581554PMC
http://dx.doi.org/10.1007/s11869-022-01271-3DOI Listing

Publication Analysis

Top Keywords

cape town
24
durban cape
16
column levels
12
johannesburg durban
12
south africa
8
0
6
cape
6
town
6
south
5
johannesburg
5

Similar Publications

Introduction: Emergency care begins in the community, who are often the first on the scene. Where emergency care systems are nascent or absent, bystanders represent the only prehospital emergency care that victims might receive. It is important to equip bystanders through life-saving skills training (LST).

View Article and Find Full Text PDF

AAV Capsid Modification and Its Influence on Viral Protein Stoichiometry and Packaging Fitness: Current Understandings and Future Direction.

Mol Biotechnol

January 2025

Medical Biotechnology and Immunotherapy Research Unit, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, 7700, South Africa.

The field of gene therapy has witnessed significant advancements in the utilization of Adeno-associated virus (AAV) owing to its inherent biological advantages. Targeted AAV vectors are generated through genetic or chemical modification of the capsid for user-directed purposes. However, this process can result in imbalances in viral protein sequence homogeneity, stoichiometry, and functional transduction vector units, thereby introducing new challenges.

View Article and Find Full Text PDF

Background: Nurses play a pivotal role in the provision of health care for children across Africa. With limited pediatric nursing content in undergraduate nursing programs and few available pediatric postgraduate nursing programs, there is a need for additional continuing professional development opportunities to prepare nurses with the knowledge, skills, and confidence needed to care for children.

Method: To address this need, and mindful of the unique profile of potential participants, the Children's Nursing Development Unit at the University of Cape Town developed a suite of asynchronous short online courses.

View Article and Find Full Text PDF

Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.

N Engl J Med

January 2025

From Médecins Sans Frontières (L.G., F.V.), Sorbonne Université, INSERM Unité 1135, Centre d'Immunologie et des Maladies Infectieuses (L.G.), Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux (L.G.), and Epicentre (M.G., E. Baudin), Paris, and Translational Research on HIV and Endemic and Emerging Infectious Diseases, Montpellier Université de Montpellier, Montpellier, Institut de Recherche pour le Développement, Montpellier, INSERM, Montpellier (M.B.) - all in France; Interactive Development and Research, Singapore (U.K.); McGill University, Epidemiology, Biostatistics, and Occupational Health, Montreal (U.K.); UCSF Center for Tuberculosis (G.E.V., P.N., P.P.J.P.) and the Division of HIV, Infectious Diseases, and Global Medicine (G.E.V.), University of California at San Francisco, San Francisco; the National Scientific Center of Phthisiopulmonology (A.A., E. Berikova) and the Center of Phthisiopulmonology of Almaty Health Department (A.K.), Almaty, and the City Center of Phthisiopulmonology, Astana (Z.D.) - all in Kazakhstan; Médecins Sans Frontières (C.B., I.M.), the Medical Research Council Clinical Trials Unit at University College London (I.M.), and St. George's University of London Institute for Infection and Immunity (S.W.) - all in London; MedStar Health Research Institute, Washington, DC (M.C.); Médecins Sans Frontières, Mumbai (V. Chavan), the Indian Council of Medical Research Headquarters-New Delhi, New Delhi (S. Panda), and the Indian Council of Medical Research-National AIDS Research Institute, Pune (S. Patil) - all in India; the Centre for Infectious Disease Epidemiology and Research (V. Cox) and the Department of Medicine (H. McIlleron), University of Cape Town, and the Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine (S.W.) - both in Cape Town, South Africa; the Institute of Tropical Medicine, Antwerp, Belgium (B. C. J.); Médecins Sans Frontières, Geneva (G.F., N.L.); Médecins Sans Frontières, Yerevan, Armenia (O.K.); the National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia (N.K.); Partners In Health (M.K.) and Jhpiego Lesotho (L.O.) - both in Maseru; Socios En Salud Sucursal Peru (L.L., S.M.-T., J.R., E.S.-G., D.E.V.-V.), Hospital Nacional Sergio E. Bernales, Centro de Investigacion en Enfermedades Neumologicas (E.S.-G.), Hospital Nacional Dos de Mayo (E.T.), Universidad Nacional Mayor de San Marcos (E.T.), and Hospital Nacional Hipólito Unanue (D.E.V.-V.) - all in Lima; Global Health and Social Medicine, Harvard Medical School (L.L., K.J.S., M.L.R., C.D.M.), Partners In Health (L.L., K.J.S., M.L.R., C.D.M.), the Division of Global Health Equity, Brigham and Women's Hospital (K.J.S., M.L.R., C.D.M.), the Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, (L.T.), and Harvard T.H. Chan School of Public Health (L.T.) - all in Boston; and the Indus Hospital and Health Network, Karachi, Pakistan (H. Mushtaque, N.S.).

Background: For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs to treat tuberculosis and enhanced funding now permit randomized, controlled trials of shortened-duration, all-oral treatments for rifampin-resistant tuberculosis.

Methods: We conducted a phase 3, multinational, open-label, randomized, controlled noninferiority trial to compare standard therapy for treatment of fluoroquinolone-susceptible, rifampin-resistant tuberculosis with five 9-month oral regimens that included various combinations of bedaquiline (B), delamanid (D), linezolid (L), levofloxacin (Lfx) or moxifloxacin (M), clofazimine (C), and pyrazinamide (Z).

View Article and Find Full Text PDF

Acellular Dermal Matrices in Reconstructive Pediatric Complex Lower Limb Trauma: An Observational Study.

J Trauma Nurs

January 2025

Author Affiliations: St Andrew's Anglia Ruskin (StAAR) Research Group, Faculty of Health, Education, Medicine, and Social Care, Anglia Ruskin University, Chelmsford, UK (Dr Adegboye); Division of Plastic and Reconstructive Surgery, Red Cross War Memorial Children's Hospital; and Division of Plastic & Reconstructive Surgery, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa (Dr Pillay and Prof Adams).

Background: Contemporary research has shown that acellular dermal matrices can benefit adult lower extremity traumatic injuries; however, its use in children has not been explored.

Objective: This study aims to explore the use of acellular dermal matrices in pediatric complex lower extremity trauma.

Methods: This single-center retrospective observational cohort study of children with complex lower extremity trauma treated with Pelnac™, commercial acellular dermal matrices, was conducted at a tertiary hospital in South Africa from 2010 to 2017.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!